Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 34 Neoplasm Metastasis 7 Neoplasms 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Squamous Cell 2 Breast Neoplasms, Male 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Metastatic Breast Cancer With Intracranial Metastases 1 Melanoma 1 Inflammatory Breast Neoplasms 1 Her2 Positive Metastatic Breast Cancer 1 Head and Neck Neoplasms 1 HER2 Positive Esophagogastric Cancer 1 GastroEsophageal Cancer 1 Esophageal Squamous Cell Carcinoma 1 Diarrhea 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Ductal, Breast 1 Carcinoma 1 Breast Diseases 1 Brain Neoplasms 1

Interventions

Dexamethasone 29 Cyclophosphamide 21 Rituximab 17 Cytarabine 16 Bortezomib 13 Gemcitabine 12 fludarabine 11 Methotrexate 11 Lenalidomide 10 Filgrastim 10 Vincristine 9 Etoposide 9 pomalidomide 8 pembrolizumab 8 Paclitaxel 8 Azacitidine 8 venetoclax 7 carfilzomib 7 Doxorubicin 7 Docetaxel 7 Cyclosporine 7 Calcium Dobesilate 7 Antilymphocyte Serum 7 fludarabine phosphate 6 Topotecan 6 Temozolomide 6 Radiotherapy 6 Peripheral Blood Stem Cell Transplantation 6 Mitoxantrone 6 daratumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × Lapatinib × Clear all

NCT00888810 2009-04-28

TOPO-LAPA

Centre Francois Baclesse

Phase 2 Terminated

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡